NCT05683184PHASE1RecruitingAccepts Healthy Volunteers

OMAR Opioid Use Disorder

Yale University

Start Date

3/10/2023

Completion Date

12/15/2026

Summary

The goal of this research study is to examine the endocannabinoid (eCB) function in vivo in individuals with opioid use disorder (OUD) by measuring cannabinoid receptor 1 (CB1R) availability.

Detailed Description

The investigators will image brain cannabinoid receptors using Positron Emission Tomography (PET) imaging and the radioligand \[11C\] OMAR, in healthy individuals and individuals diagnosed with opioid use disorder. Research participants may complete screening, MRI, PET scan and follow up visits.

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: * Able to provide informed consent * Male and female 18 years and older * DSM-5 diagnosis of opioid use disorder (for OUD group) * Physically healthy i.e., no clinically unstable medical conditions * Written informed consent and have capacity to consent and comply with study procedures Exclusion Criteria: * Current neuro-psychiatric illness or severe systemic disease (opioid use disorder is permitted in the OUD group). * Presence of ferromagnetic metal in the body or heart pacemaker * Have had exposure to ionizing radiation that in combination with the study tracer would result in a cumulative exposure that exceeds recommended exposure limits * Are claustrophobic

Interventions

DRUG

[11C]OMAR

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Healthy ControlOpioid Use Disorder

Locations

Connecticut Mental Health Center, Clinical Neuroscience Research Unit

New Haven, Connecticut 06519

United States